The U.S. Food and Drugs Administration (FDA) ordered the total recall of a number of drugs, including Valsartan, said to be of high risk to human health from markets.
According to Mohamed Farah Qotti, Coordinator of Health Packages of the Somaliland Ministry of Health development, the FDA released a circular blowing the whistle on drugs such as Valsartan, which is found to contain a chemical substance called N-nitrosodimethylamine (DNDMA) which is a cogent agent that can cancer cells in the human body.
Valsartan is normally used to treat high blood pressure and heart failure.
Last month, the FDA issued a voluntary recall of certain batches of the drug but has since expanded its recall two additional times to include more valsartan-containing products.
The FDA recall already prompted 52 countries to wholly ban the drug from both retail and wholesale markets in respective countries.
Balsam Pharmaceutical, a drugs importer in Somaliland, heeding the call, handed over 3020 cartons of Camoval, comprising of Amlodipine 5mg + Valsartan 160mg and Amplopidine 5mg + Valsartan 80mg, to the Ministry of Health for safe disposal.
A Ministry spokesman, Abdullahi Abdi Yussuf, following up on the FDA circular called on all pharmaceutical dealers in the country, whether that be in retail or in wholesale, to report stocks of the tainted drugs.
“Anybody who infringes on the call made and is found to be using or trading in the drugs specified will have to answer to the law,” he said.
Somaliland offers a hardly monitored free market to all sorts of shady – most often risky – drugs. Of late, a host of cancer variants, acute heart conditions, kidney failure, seizures, rheumatism-related cases, and other highly debilitating medical conditions, which were unknown in these areas a decade or so ago, have risen to alarming levels.
The steps that the FDA and the Ministry of Health have taken infuse a welcome breath into hitherto lifeless ministry activities, especially in asserting a discernible influence on drugs, drug use, hospitals and health practitioners. The Ministry started training a closer look upon practicing doctors to certify qualifications and fields of expertise.
FDA Expands Valsartan Products Recall
The agency also has revised information regarding A-S Medication Solutions on the list of recalled products.1
The products being recalled contain an impurity, N-nitrosodimethylamine (NDMA) in the active pharmaceutical ingredient (API) valsartan manufactured by Zhejiang Huahai Pharmaceuticals of Linhai, China.2 NDMA is classified as a probable human carcinogen.2
Some companies are recalling all lots of unexpired products that contain the ingredient valsartan supplied by a third party. Not all valsartan-containing medicines distributed in the United States have valsartan API supplied by Zhejiang Huahai Pharmaceuticals.2,3The supplier has stopped distributing its valsartan API.3
The recalled products include Valsartan, Actavis; Valsartan, A-S Medication Solutions LLC; Valsartan, Bryant Ranch Prepack Inc.; Valsartan, Northwind Pharmaceuticals.Valsartan, Prinston Pharmaceuticals’ Solco Healthcare; and Valsartan, Teva Pharmaceuticals’ Major Pharmaceuticals.4
Also recalled are Valsartan/Hydrochlorothiazide (HCTZ), Actavis; Valsartan/Hydrochlorothiazide (HCTZ), AvKARE; Valsartan/Hydrochlorothiazide (HCTZ), A-S Medication Solutions LLC; Valsartan/Hydrochlorothiazide (HCTZ), Northwind Pharmaceuticals; Valsartan/Hydrochlorothiazide (HCTZ), Prinston Pharmaceuticals’ Solco Healthcare; Valsartan/Hydrochlorothiazide (HCTZ), Proficient Rx LP; and Valsartan/Hydrochlorothiazide (HCTZ), Remedy Repack.4
A-S Medication Solutions is a repackager that used NDC for valsartan products made by Prinston Pharmaceuticals and Teva Pharmaceuticals, labeled as Solco Healthcare and Actavis, respectively, according to the FDA.
Lot numbers of all the recalled products can be found on the FDA’s website.
The FDA is working with drug manufacturers to ensure that future valsartan APIs are not at risk of NDMA formation.
FDA Commissioner Scott Gottlieb, MD, said in a statement that the agency is committed to efficacy and safety.2
“When we identify lapses in the quality of drugs and problems with their manufacturing that have the potential to create risks to patients, we’re committed to taking swift action to alert the public and help facilitate the removal of the products from the market,” he said.2 “As we seek the removal of certain drug products, our drug shortages team is also working hard to ensure patients’ therapeutic needs are met in the United States with an adequate supply of unaffected medications.”
In addition to its list of recalled products, the FDA is maintaining a list of other products containing valsartan that are not being recalled. Among the non-recalled items are Alembic products including its Valsartan, which is produced internally and does not contain outsourced ingredients, according to the company.5
- FDA. FDA updates recalled valsartan-containing product information and reminds API manufacturers to evaluate processes for unsafe impurities. www.fda.gov/drugs/drugsafety/ucm613916.htm. Published August 2, 2018. Accessed August 8, 2018.
- FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity [news release]. Silver Spring, MD; July 13, 2018. FDA website. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm61353htm. Accessed August 8, 2018.
- Voluntary recall of several medicines containing valsartan following impurity detection. Pharmacy Times. pharmacytimes.com/news/voluntary-recall-of-several-medicines-containing-valsartan-following-impurity-detection-. Published July 15, 2018. Accessed August 8, 2018.
- FDA. Products subject to the valsartan recall – updated August 2, 2018. www.fda.gov/downloads/Drugs/DrugSafety/UCM615703.pdf. Accessed August 8, 2018.
- Alembic: Valsartan products not subject to recall. Pharmacy Times. pharmacytimes.com/news/alembics-valsartancontaining-products-not-subject-to-fda-recall-. Published July 31, 2018. Accessed August 8, 2018.